{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:03:03Z","timestamp":1787241783125,"version":"build-2736575974"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mitoxantrone hydrochloride liposome (Lipo-MIT) exhibits encouraging efficacy in treating multiple hematologic malignancies. This study evaluated the real-world efficacy and safety of Lipo-MIT-containing regimens in the treatment of acute myeloid leukemia (AML).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This noninterventional, ambispective cohort study was conducted at 42 centers in China. Patients with newly diagnosed or relapsed\/refractory AML who received Lipo-MIT-containing regimens were included. The primary endpoint was the composite complete remission (CRc) rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between January 2022 and December 2023, 117 patients with newly diagnosed AML and 122 patients with relapsed\/refractory AML were included. The CRc and objective response rates were 84.6% (95% confidence interval [CI], 76.8-90.6) and 91.5% (95% CI, 84.8-95.8), respectively, in the newly diagnosed AML, and 45.1% (95% CI, 36.1-54.3) and 55.7% (95% CI, 46.5-64.7), respectively, in relapsed\/refractory AML. The 2-year-event-free survival and overall survival rates for newly diagnosed AML were 67.0% (95% CI, 54.4-76.8) and 77.8% (95% CI, 63.8-86.9), respectively, while the rates for relapsed\/refractory AML were 23.9% (95% CI, 12.5-37.3) and 56.9% (95% CI, 39.6-70.9), respectively. Univariate and multivariate analyses suggested age and the number of prior failed induction therapy cycles as independent prognostic factors for CRc in relapsed\/refractory AML (all P\u2009&amp;lt;\u2009.05). Treatment-related adverse events (AEs) were reported in 216 patients (90.4%). Thrombocytopenia (64.4%), leukopenia (63.6%), and neutropenia (60.7%) were the most common AEs of grade 3-4. No treatment-related deaths occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lipo-MIT-containing regimens were effective and well-tolerated in AML under real-world circumstances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration ID<\/jats:title>\n                    <jats:p>ChiCTR2200067172<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf304","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:02:03Z","timestamp":1760097723000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemia"],"prefix":"10.1093","volume":"30","author":[{"given":"Tie-Jun","family":"Gong","sequence":"first","affiliation":[{"name":"Harbin Institute of Hematology & Oncology, Harbin the First Hospital , Harbin, 150010,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430022,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tangdu Hospital , Xi \u2018an, 710038,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Henan Provincial People\u2019s Hospital , Zhengzhou, 450003,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Bethune Hospital of Jilin University , Changchun, 130021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shengjing Hospital of China Medical University , Shenyang, 110004,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Anhui Provincial Hospital , Hefei, 230001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Chuan","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University , Chongqing, 400010,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zibo Central Hospital , Zibo, 250036,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Hospital of Hebei Medical University , Shijiazhuang, 050000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Hematology, Second Hospital of Shanxi Medical University , Taiyuan, 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sichuan Provincial People\u2019s Hospital , Chengdu, 610072,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhejiang Provincial People\u2019s Hospital , Hangzhou, 310014,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Song","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Third Bethune Hospital of Jilin University , Changchun, 130033,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hong","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Lymphatic Hematology and Pediatric Oncology, Guangxi Medical University Cancer Hospital , Nanning, 530200,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Cheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430030,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Cheng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xi\u2019an Jiao Tong University , Xi\u2019an, 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yantai Yuhuangding Hospital , Yantai, 264000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Bengbu Medical College , Bengbu, 233004,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hu","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fuyang People\u2019s Hospital , Fuyang, 236001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Dong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Henan Cancer Hospital , Zhengzhou, 450003,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital , Nanjing, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiangsu Province Hospital , Nanjing, 210029,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Zhi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shandong Provincial Hospital , Jinan, 250021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Xiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, 430014,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jing","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of China Medical University , Shenyang, 110001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Ping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Kunming Medical University , Kunming, 650101,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, 200127,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine , Tianjin, 300193,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7635-281X","authenticated-orcid":false,"given":"Jun","family":"Ma","sequence":"additional","affiliation":[{"name":"Harbin Institute of Hematology & Oncology, Harbin the First Hospital , Harbin, 150010,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2025102712571050500_oyaf304-B1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"key":"2025102712571050500_oyaf304-B2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"D\u00f6hner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025102712571050500_oyaf304-B3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"2025102712571050500_oyaf304-B4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood.2022018092","article-title":"Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets","volume":"141","author":"Mishra","year":"2023","journal-title":"Blood"},{"key":"2025102712571050500_oyaf304-B5","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"2025102712571050500_oyaf304-B6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/asheducation-2009.1.385","article-title":"Independent prognostic factors for AML outcome","author":"Grimwade","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2025102712571050500_oyaf304-B7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am J Hematol"},{"key":"2025102712571050500_oyaf304-B8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2025102712571050500_oyaf304-B9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"2025102712571050500_oyaf304-B10","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1200\/jco.2018.78.7366","article-title":"Improved survival by adding lomustine to conventional chemotherapy for elderly patients with AML without unfavorable cytogenetics: results of the LAM-SA 2007 FILO trial","volume":"36","author":"Pigneux","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025102712571050500_oyaf304-B11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.leu.2403336","article-title":"Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study","volume":"18","author":"Holowiecki","year":"2004","journal-title":"Leukemia"},{"key":"2025102712571050500_oyaf304-B12","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/jco.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025102712571050500_oyaf304-B13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/9781118853771.ch20","volume-title":"Postgraduate Haematol","author":"Burnett","year":"2015"},{"key":"2025102712571050500_oyaf304-B14","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"2025102712571050500_oyaf304-B15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"2025102712571050500_oyaf304-B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41417-019-0119-5","article-title":"Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia","volume":"27","author":"Cui","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"2025102712571050500_oyaf304-B17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3324\/haematol.2022.280798","article-title":"New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia","volume":"108","author":"Mohty","year":"2023","journal-title":"Haematologica"},{"key":"2025102712571050500_oyaf304-B18","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3324\/haematol.2022.281810","article-title":"Maintenance therapy in acute myeloid leukemia: advances and controversies","volume":"108","author":"Senapati","year":"2023","journal-title":"Haematologica"},{"key":"2025102712571050500_oyaf304-B19","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2165\/00003495-199141030-00007","article-title":"Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer","volume":"41","author":"Faulds","year":"1991","journal-title":"Drugs"},{"key":"2025102712571050500_oyaf304-B20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/med.21364","article-title":"Mitoxantrone, more than just another topoisomerase II poison","volume":"36","author":"Evison","year":"2016","journal-title":"Med Res Rev"},{"key":"2025102712571050500_oyaf304-B21","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/j.clml.2020.08.001","article-title":"Effect of dose ratio on mitoxantrone and daunorubicin in acute myeloid leukemia: a systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Deng","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025102712571050500_oyaf304-B22","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/jco.2009.22.9088","article-title":"Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial","volume":"28","author":"Burnett","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025102712571050500_oyaf304-B23","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1200\/jco.1991.9.7.1210","article-title":"Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia","volume":"9","author":"Amadori","year":"1991","journal-title":"J Clin Oncol"},{"key":"2025102712571050500_oyaf304-B24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00277-006-0121-5","article-title":"Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the polish adult leukemia group (PALG)","volume":"85","author":"Giebel","year":"2006","journal-title":"Ann Hematol"},{"key":"2025102712571050500_oyaf304-B25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ajh.2830430307","article-title":"Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia","volume":"43","author":"Schiller","year":"1993","journal-title":"Am J Hematol"},{"key":"2025102712571050500_oyaf304-B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4068\/cmj.2021.57.1.27","article-title":"Liposomes: biomedical applications","volume":"57","author":"Kim","year":"2021","journal-title":"Chonnam Med J"},{"key":"2025102712571050500_oyaf304-B27","first-page":"81","article-title":"Development of liposomal formulations: from concept to clinical investigations","volume":"8","author":"Fan","year":"2013","journal-title":"Asian J Pharm Sci"},{"key":"2025102712571050500_oyaf304-B28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00280-014-2523-8","article-title":"Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy","volume":"74","author":"Yang","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025102712571050500_oyaf304-B29","doi-asserted-by":"publisher","first-page":"e35672","DOI":"10.1002\/cncr.35672","article-title":"Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: a phase 2, multicenter, open-label, single-arm trial","volume":"131","author":"Gao","year":"2025","journal-title":"Cancer"},{"key":"2025102712571050500_oyaf304-B30","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1002\/hem3.104","article-title":"PB2460) Efficacy and tolerability of combined regimens with mitoxantrone hydrochloride liposome for refractory and relapsed acute myeloid leukemia","volume":"8","author":"Lu","year":"2024","journal-title":"Hemasphere"},{"key":"2025102712571050500_oyaf304-B31","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1002\/hem3.104","article-title":"P1823) Combination of mitoxantrone hydrochloride liposome with cytarabine in pediatric patients with newly diagnosed AML: pharmacokinetics, safety and efficacy","volume":"8","author":"Yang","year":"2024","journal-title":"Hemasphere"},{"key":"2025102712571050500_oyaf304-B32","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1002\/hem3.104","article-title":"P1749) Efficacy and safety of mitoxantrone hydrochloride liposome combined with CLAG regimen in refractory and relapsed acute myeloid leukemia (non-M3)","volume":"8","author":"Wan","year":"2024","journal-title":"Hemasphere"},{"key":"2025102712571050500_oyaf304-B33","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/s2666-7568(22)00186-6","article-title":"Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43\u2008895 trials and 5\u2008685\u2008738 individuals across 989 unique drugs and 286 conditions in England","volume":"3","author":"Tan","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"2025102712571050500_oyaf304-B34","doi-asserted-by":"publisher","first-page":"7039","DOI":"10.1200\/JCO.2023.41.16_suppl.7039","article-title":"Analysis of short-term efficacy and safety of mitoxantrone hydrochloride liposome regimen therapy in adult acute myeloid leukemia","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025102712571050500_oyaf304-B35","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2025102712571050500_oyaf304-B36","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"2025102712571050500_oyaf304-B37","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/jco.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025102712571050500_oyaf304-B38","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/s2352-3026(22)00106-5","article-title":"Venetoclax plus 3\u2009+\u20097 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol"},{"key":"2025102712571050500_oyaf304-B39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2014-10-551911","article-title":"How I treat refractory and early relapsed acute myeloid leukemia","volume":"126","author":"Thol","year":"2015","journal-title":"Blood"},{"key":"2025102712571050500_oyaf304-B40","doi-asserted-by":"publisher","first-page":"106300","DOI":"10.1016\/j.leukres.2020.106300","article-title":"Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo clinic cancer center: analysis of survival after \u2018CLAG-M\u2019 vs. \u2018MEC\u2019","volume":"90","author":"Scheckel","year":"2020","journal-title":"Leuk Res"},{"key":"2025102712571050500_oyaf304-B41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1600-0609.2007.00988.x","article-title":"Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the polish adult leukemia group","volume":"80","author":"Wierzbowska","year":"2008","journal-title":"Eur J Haematol"},{"key":"2025102712571050500_oyaf304-B42","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00277-022-04883-y","article-title":"Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis","volume":"101","author":"Wolach","year":"2022","journal-title":"Ann Hematol"},{"key":"2025102712571050500_oyaf304-B43","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1200\/jco.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025102712571050500_oyaf304-B44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2025102712571050500_oyaf304-B45","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3324\/haematol.2014.114157","article-title":"ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian acute myeloid leukemia study group","volume":"100","author":"Paschka","year":"2015","journal-title":"Haematologica"},{"key":"2025102712571050500_oyaf304-B46","first-page":"36","article-title":"Safety and efficacy of mitoxantrone hydrochloride liposome in patients with relapsed or refractory peripheral T-cell lymphoma and extranodal NK\/T-cell lymphoma: a prospective, single-arm, open-label, multi-center, phase II clinical trial","volume":"136","author":"Gao","year":"2020","journal-title":"Blood"},{"key":"2025102712571050500_oyaf304-B47","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1182\/blood-2023-185669","article-title":"Mitoxantrone hydrochloride liposome, gemcitabine, vinorelbine with or without rituximab (GVM\u00b1R) in patients with relapsed or refractory aggressive non-Hodgkin\u2019s \u00adlymphoma","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf304\/64660140\/oyaf304.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf304\/64660140\/oyaf304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf304\/64660140\/oyaf304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:57:17Z","timestamp":1761584237000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf304\/8284930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf304","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10,1]]},"article-number":"oyaf304"}}